{"id":250961,"date":"2025-02-07T00:00:00","date_gmt":"2025-02-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidon0029-biopharma-non-small-cell-lung-cancer-epidemiology-mature\/"},"modified":"2026-03-31T10:27:08","modified_gmt":"2026-03-31T10:27:08","slug":"epidon0029-biopharma-non-small-cell-lung-cancer-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0029-biopharma-non-small-cell-lung-cancer-epidemiology-mature-markets\/","title":{"rendered":"Non-Small-Cell Lung Cancer &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of non-small-cell lung cancer (<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the world.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> per year?<\/li>\n<li>In developing countries, what impact will economic growth and development have on the number of first-line drug-treatment opportunities for <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>?<\/li>\n<li>How will improvements in survival change the number of people living with <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>?<\/li>\n<li>Of all people diagnosed with <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>, how many in each country across the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr data-abbreviation-entity=\"10739\" title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.<\/p>\n<p>In total, Clarivate Epidemiology forecasts over 100 <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> patient populations, including the following:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> by stage.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> by histology.<\/li>\n<li>Diagnosed metastatic recurrent incident cases of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> by histology.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> by histology.<\/li>\n<li>Diagnosed first-line <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> metastatic drug-treatable population.<\/li>\n<li>Diagnosed <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> drug-treated population.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250961","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250961\/revisions"}],"predecessor-version":[{"id":567742,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250961\/revisions\/567742"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}